N-terminal selective conjugation method widens the therapeutic window of antibody–drug conjugates by improving tolerability and stability

Antibody–drug conjugates (ADCs) are targeted therapeutic agents that treat cancers by selective delivery of highly potent cytotoxic drugs to tumor cells via cancer-specific antibodies. However, their clinical benefit is limited by off-target toxicity and narrow therapeutic windows. To overcome these...

Descripción completa

Detalles Bibliográficos
Autores principales: Ko, Min Ji, Song, Daehae, Kim, Juhee, Kim, Jae Yong, Eom, Jaehyun, Sung, Byungje, Son, Yong-Gyu, Kim, Young Min, Lee, Sang Hoon, You, Weon-Kyoo, Jung, Jinwon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8081041/
https://www.ncbi.nlm.nih.gov/pubmed/33904380
http://dx.doi.org/10.1080/19420862.2021.1914885

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8081041/
https://www.ncbi.nlm.nih.gov/pubmed/33904380
http://dx.doi.org/10.1080/19420862.2021.1914885

Ejemplares similares